GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
A New Lens on Alzheimer's: How GE HealthCare's Vizamyl is Revolutionizing Diagnosis and Treatment Monitoring
Imagine peering into the intricate workings of the human brain, not just to see its structure, but to uncover the subtle whispers of a disease that gradually erodes memory, thought, and ultimately, identity. For decades, Alzheimer's disease has presented a formidable challenge, often diagnosed only after significant cognitive decline has set in, and the opportunity for early intervention has diminished. But a recent development, spearheaded by the U.S. Food and Drug Administration (FDA) and GE HealthCare
Alzheimer’s Breakthrough: Why Tau-Targeting Therapies Are Changing the Game
Explore how tau-targeting drug Diranersen and a newly diversified research pipeline are reshaping Alzheimer's treatment and slowing cognitive decline.
AI Revolution: Decoding Alzheimer’s Before Symptoms Start
For decades, we’ve treated Alzheimer’s like a collapsing building. We usually don’t call the engineers until the roof is already caving in—when memory loss is so severe that it disrupts daily life. The medical criteria from 1984, which set the standard for diagnosis for a long time, were built on this "end-stage" philosophy. By the time we diagnosed the disease, the damage was often irreparable.
Why Finding 'Nothing' Is Big News: How AI Helps Rule Out Alzheimer's
When you or someone you love starts becoming a bit forgetful or feels like they are in a "fog," it is natural for your mind to jump to the scariest conclusion: Alzheimer's. That anxiety can be overwhelming, making every misplaced set of keys or forgotten name feel like a major warning sign.